The NEDD8-Activating Enzyme Inhibitor MLN4924 Disrupts Nucleotide Metabolism and Augments the Efficacy of Cytarabine

Steffan T. Nawrocki¹, Kevin R. Kelly², Peter G. Smith³,⁴, Mignon Keaton⁵,⁶, Hetty Carraway⁷, Mikkael A. Sekeres⁷, Jaroslaw P. Maciejewski⁸, and Jennifer S. Carew⁷

Abstract

Purpose: New therapies are urgently needed for patients with acute myelogenous leukemia (AML). The novel NEDDylation inhibitor MLN4924 (pevonedistat) has demonstrated significant preclinical antileukemic activity and preliminary efficacy in patients with AML in a phase I trial. On the basis of its antilymphoid and DNA-damaging properties, we investigated the ability of MLN4924 to augment conventional cytarabine (ara-C) therapy.

Experimental Design: The effects of MLN4924/ara-C on viability, clonogenic survival, apoptosis, DNA damage, and relevant pharmacodynamic targets were determined. The efficacy and pharmacodynamics of MLN4924/ara-C were assessed in an AML xenograft model.

Results: Cotreatment of AML cell lines and primary patient specimens with MLN4924 and ara-C led to diminished clonogenic survival, increased apoptosis, and synergistic levels of DNA damage. RNAi demonstrated that stabilization of CDT-1, an event previously shown to mediate the DNA-damaging effects of MLN4924, was not a key regulator of sensitivity to the MLN4924/ara-C combination. Global metabolic profiling revealed that MLN4924 disrupts nucleotide metabolism and depletes intracellular nucleotide pools in AML cells. Subsequent experiments showed that MLN4924 promoted increased incorporation of ara-C into the DNA of AML cells. This effect as well as the therapeutic benefit of the MLN4924/ara-C combination was antagonized by supplementation with the nucleotide building block ribose. Coadministration of MLN4924 and ara-C to mice bearing FLT3-ITD⁺ AML xenografts stably inhibited disease progression and increased DNA damage in vivo.

Conclusions: Our findings provide strong rationale for clinical investigation of the MLN4924/ara-C combination and establish a new link between therapeutic inhibition of NEDDylation and alterations in nucleotide metabolism. Clin Cancer Res; 21(2); 439–47.

©2014 AACR

Introduction

Acute myelogenous leukemia (AML) is a multistep, multipathway malignancy that is ultimately fatal in the majority of affected patients (1). Older adults with AML have an extremely poor prognosis and derive limited benefit from intensive chemotherapy due to their prevalence of unfavorable cytogenetics predicting chemotherapy refractoriness, preexisting myelodysplastic syndromes (MDS) associated with a limited normal functioning stem cell compartment and serial genetic lesions evolving to disease manifestation, and expression of a multidrug-resistant phenotype (2–4). No standard induction approach exists for older adults, in part, due to their poor representation in clinical studies. The last prospective trial comparing intensive chemotherapy to low-dose approaches was conducted over two decades ago (5). Although induction with low-dose cytarabine (LDAC) offers a survival advantage over supportive care for patients with good/intermediate prognosis cytogenetics, patients with poorer performance status and/or unfavorable cytogenetics have a low likelihood of achieving complete responses (CR) when treated with LDAC (1). Considering these issues, new therapeutic approaches that are effective and tolerated could be transformative particularly for older patients with AML.

Protein turnover plays a critical regulatory role in many essential cellular processes, including cell-cycle progression, signal transduction, and cell death. Aberrant ubiquitin-proteasome system (UPS)-mediated protein degradation contributes to disease progression, metastasis, and drug resistance and is thus, an appealing anticancer strategy (6). The proteasome inhibitor, bortezomib (Velcade), was the first anticancer agent of this drug class to receive FDA approval (7). Bortezomib established proof of concept that targeting protein turnover is an effective anticancer strategy and is currently indicated for the treatment of multiple myeloma and mantle cell lymphoma and in combination with cytotoxic therapy, yielded high response rates in patients with AML (8, 9). Following its success, a second proteasome inhibitor (carfilzomib) also earned FDA approval for the treatment of patients with multiple myeloma who...
rupting the NEDDylation pathway has significant and logical implications for cancer progression and/or promote therapeutic resistance, disrupting the off-target effects and toxicities that are associated with proteins, which could potentially eliminate or reduce some of the off-target effects and toxicities that are associated with global pro teaseal inhibition.

NEDD8 is a small ubiquitin-like molecule that regulates the activity of the cullin-RING family of E3 ubiquitin ligases (CRL) through covalent modification. The CRLs control the degradation of a number of proteins with essential roles in cell-cycle progression, tumor suppression, signal transduction, and responses to DNA damage and other stress stimuli, including p27, cyclin E, c-Myc, p53, phospho-IκBα, CDT-1, NRF-2, and hypoxia-inducible factor-1α (11). As degradation of these molecules could accelerate cancer progression and/or promote therapeutic resistance, disrupting the NEDDylation pathway has significant and logical therapeutic potential. MLN4924 (pevonedistat) is a first-in-class, selective small-molecule inhibitor of NEDD8-activating enzyme (NAE), the proximal regulator of the NEDDylation cascade (12–14). We previously showed that MLN4924 overcomes multiple mechanisms of prosurvival signaling, triggers DNA damage associated with CDT1 stabilization and CHK1 activation, and induces stable disease regression in an AML mouse model (15). This was confirmed in a phase I clinical trial in refractory MDS/AML patients, some of whom achieved complete responses following treatment with MLN4924 (16). The mechanistic basis for the anti-AML effects of MLN4924 remains to be fully elucidated. We conducted comprehensive metabolic profiling to further investigate the pharmacodynamic effects of MLN4924 in AML cells that contribute to its therapeutic activity and ability to augment the efficacy of ara-C.

Materials and Methods

Cells and cell culture

HL-60 and KG-1 cells were obtained from ATCC. MV4-11 and MOLM-13 cells were obtained from DSMZ. Cell lines were authenticated by the source banks using DNA profiling techniques and were used for this study in accordance with AACR guidelines. Primary human AML cells were isolated from the bone marrow of patients with AML after obtaining informed consent. All AML cells (primary and established cell lines) were cultured under identical conditions with RPMI-1640 medium supplemented with 10% FBS at 37°C with 5% CO2, as previously described (15).

Sample preparation, metabolic profiling, metabolite identification, and data analysis

The untargeted metabolic profiling platform used for this analysis combined three independent platforms: ultrahigh-performance liquid chromatography/tandem mass spectrometry (UHLC/MS–MS2) optimized for basic species, UHLC/MS–MS2 optimized for acidic species, and gas chromatography–mass spectrometry. Detailed methods for the metabolomic analyses are available as an online supplement.

Chemicals and reagents

Reagents were obtained from: cytarabine (ara-C, Hospira, Inc.), anti-active caspase-3, anti-p27, anti-CDT1 (Cell Signaling Technology), anti-phospho-Ser117, and total CHK1, and γH2AX antibodies (Epitomics), anti-β-tubulin and ribose (Sigma), antiproliferating cell nuclear antigen (PCNA; Dako), goat anti-rabbit horseradish peroxidase (HRP)-conjugated secondary antibody (Jackson Laboratories), rat anti-mouse IgG2a–HRP antibody (Serotec), sheep anti-mouse-HRP, and donkey anti-rabbit–HRP (Amersham).

Cell viability assay

Cells were plated in triplicate and treated with defined concentrations of MLN4924, ara-C, or both drugs for 72 hours. Viable cells were quantified using ATPLite according to the manufacturer’s instructions (PerkinElmer) as previously described (14, 15, 17).

Synergy analyses

The combination indices (CI) for MLN4924 and ara-C were calculated on the basis of the effect of 72-hour exposure to each drug on cell viability as determined by ATPLite assay. CompuSyn software (CompuSyn, Inc.) software was utilized to calculate CI values as previously described (18).

Analysis of drug-induced apoptosis

Drug-induced apoptosis was quantified by PI/FACS analysis of sub-G0/G1 DNA content as previously described (17, 19).

Colony assays

AML cells were treated with the indicated concentrations of MLN4924, ara-C, or both drugs for 24 hours. Drugs were washed away and cells were seeded in Methocult methylcellulose-containing medium. Colonies were stained and scored as previously described (15, 20).

Immunoblotting

AML cells were incubated with MLN4924, ara-C, or the combination of both drugs for 24 hours as indicated. Cells were then lysed for 1 hour on ice in Triton X-100 lysis buffer (1% Triton X-100, 150 mmol/L NaCl, 25 mmol/L Tris, pH 7.5) with protease inhibitors. Proteins were separated by SDS-PAGE and transferred

Translational Relevance

Novel therapeutic strategies are urgently needed to improve the survivability of patients with acute myelogenous leukemia (AML). MLN4924 (pevonedistat) is a first-in-class NEDDylation inhibitor currently under investigation in multiple clinical trials. Here, we report that MLN4924 significantly augments the efficacy of conventional cytarabine (ara-C) therapy in preclinical models of AML and primary patient specimens. Global metabolic profiling analyses demonstrated that MLN4924 disrupted nucleotide metabolism and diminished intracellular nucleotide pools. These effects were associated with increased DNA damage and augmented incorporation of ara-C into the DNA of AML cells. Coadministration of MLN4924 and ara-C to mice bearing FLT3-ITD AML xenografts stably inhibited disease progression and increased DNA damage in vivo. Our findings provide strong rationale for clinical investigation of the MLN4924/ara-C combination.

Global metabolic profiling analyses demonstrated that MLN4924 disrupted nucleotide metabolism and diminished intracellular nucleotide pools. These effects were associated with increased DNA damage and augmented incorporation of ara-C into the DNA of AML cells. Coadministration of MLN4924 and ara-C to mice bearing FLT3-ITD AML xenografts stably inhibited disease progression and increased DNA damage in vivo. Our findings provide strong rationale for clinical investigation of the MLN4924/ara-C combination.
to nitrocellulose membranes. Blots were probed with the indicated antibodies and bands were detected by enhanced chemiluminescence (Alpha Innotech) as previously described (21). β-tubulin documented equal loading.

Alkaline comet assay
AML cells were treated with MLN4924, ara-C, or both drugs for 24 hours. Comet assays were performed using the CometAssay kit (Trevigen) according to the manufacturer’s instructions as previously described (17). Cells were imaged using fluorescent microscopy and tail moments (product of DNA amount in tail and distance of tail migration) from 50 cells per slide were calculated.

shRNA knockdown of CDT1
MOLM-13 human AML cells were infected with lentiviral particles containing nontargeted (control) or targeted shRNA directed at CDT1 (Santa Cruz Biotechnology) according to the manufacturer’s instructions. Positively infected cells were selected with puromycin treatment. Infected cells were treated with the indicated concentrations of MLN4924 and ara-C for 48 hours. Drug-induced apoptosis was quantified by PI/FACS. Knockdown efficiency was assessed by immunoblotting.

Quantification of [3H]ara-C DNA incorporation
[3H]ara-C was purchased from Moravek Biochemicals. The incorporation of [3H]ara-C into AML cells was evaluated using the method developed by Kufe and colleagues (22). Briefly, cells were incubated with non-radiolabeled MLN4924, ribose, or the combination of MLN4924 and ribose in the presence and absence [3H]ara-C for 24 hours. Cells were washed twice in PBS and total DNA was isolated from cells in all experimental groups using the DNeasy kit according to the manufacturer’s instructions (Qiagen). DNA concentrations of each sample were quantified by spectrophotometry and normalized. An equivalent amount of DNA from each sample was diluted in 1 mL of scintillation fluid and [3H] counts were determined using a standard liquid scintillation method (Beckman-Coulter).

In vivo evaluation of MLN4924 and ara-C
MOLM-13 FLT3-ITD+ human leukemia cells were injected into the flanks of nude mice as previously described (23). After tumor growth reached 150 mm³, mice were randomly assigned (n = 10 per group for all regimens) to receive vehicle control, 60 mg/kg MLN4924 BID, 50 mg/kg ara-C QD, or the combination of both drugs for 21 days. Tumor growth and animal toxicity was assessed as previously described (24).

IHC
Paraffin-embedded tumor sections were deparaffinized in xylene, exposed to a graded series of alcohol, and rehydrated in PBS (pH 7.5). Heat-induced epitope retrieval on paraffin-embedded sections and probing with specific antibodies was conducted as previously described (17). Positive reactions were visualized using 3,3′-diaminobenzidine (Dako). Images were captured using an Olympus fluorescent microscope with a DP71 camera and a 20× objective. Image-Pro Plus software Version 6.2 1 (MediaCybernetics) was used for image acquisition. Imagemod software was used for quantification of γH2AX and p27 levels by densitometric analysis of five random fields containing viable tumor cells. Quantification of PCNA and cleaved caspase-3 was conducted

Figure 1. MLN4924 and ara-C cooperate to diminish clonogenic survival and trigger apoptosis. A, the combination of MLN4924 and ara-C potently reduces the viability of AML cells. MOLM-13, MV4-11, HL-60, and KG-1 cell lines were treated with 100 nmol/L MLN4924, 100 nmol/L ara-C, or both drugs for 72 hours. Viability was assessed by the ATPLite assay. n = 3 ± SD. B, the MLN4924/ara-C combination has activity in primary AML cells. Primary cells were obtained from 10 patients with AML (n = 4 newly diagnosed, n = 6 previously treated). Patient characteristics are detailed in Supplementary Table S1. Primary cells were treated with MLN4924, ara-C, or both drugs for 72 hours. Viability was assessed by the ATPLite assay. C, inhibition of clonogenic survival following treatment with MLN4924 and ara-C. MV4-11, HL-60, KG-1, MOLM-13, and primary AML cells were treated with MLN4924, ara-C, or both drugs for 24 hours. Drug was washed away, cells were seeded in Methocult, and colonies were scored on day 10. n = 3; bars represent the mean ± SD. D, quantification of drug-induced apoptosis. MOLM-13, KG-1, HL-60, and MV4-11 cells were treated with 100 nmol/L MLN4924, 100 nmol/L ara-C, or both drugs for 48 hours. Percentages of cells with subdiploid DNA were determined by PI/FACS. n = 3 ± SD; *P < 0.05 indicates a significant difference from either single-agent treatment.
by counting the number of positive cells in five random fields as previously described (25).

Statistical analyses
Statistical significance of differences observed between samples was determined using the Tukey–Kramer comparison test or the Student t test. Differences were considered significant in all experiments at $P < 0.05$ with two-sided comparisons.

Results
MLN4924 and ara-C cooperate to antagonize clonogenic survival and trigger apoptosis
To investigate inhibiting NEDDylation with MLN4924 as a novel approach to increase the anti-AML activity of ara-C, we first treated four human AML cell lines (MV4-11, MOLM-13, HL-60, and KG-1) with MLN4924, ara-C, or both drugs for 72 hours and quantified the resulting impact of drug exposure on cell viability by ATPLite assay. Pilot drug sequencing studies showed that pretreatment with one drug first for 24 hours followed by the other agent for the remainder of the assay period did not yield significantly different antileukemic effects as compared with simultaneous drug treatment (not shown). We therefore used simultaneous treatment conditions for all in vitro combination assays in this study. Combined treatment with MLN4924 and ara-C reduced cell viability significantly more effectively than either single agent (Fig. 1A). Formal synergy analyses demonstrated a CI range of 0.5 to 0.8 across all concentrations tested. CI values less than 1.0 indicate synergy. Notably, FLT3-ITD status did not appear to affect cellular sensitivity to this combination as cells with (MV4-11 and MOLM-13) and without (HL-60, KG-1) FLT3-ITD expression benefited similarly from treatment with MLN4924 and ara-C. Treatment of primary AML blasts from patients ($n = 10$) with MLN4924 and ara-C resulted in a significantly greater reduction in viability than treatment with single agents.

Figure 2.
Induction of DNA damage by MLN4924 and ara-C. A, MLN4924 and ara-C activate the DNA damage response. Cells were treated with 100 nmol/L MLN4924, 100 nmol/L ara-C, or both drugs for 24 hours, lysed, subjected to SDS-PAGE, and probed with p27, pCHK1 (Ser317), total CHK1, γH2AX, and cleaved (active) caspase-3-specific antibodies. Tubulin documented equal loading. B and C, induction of DNA damage by MLN4924 and ara-C. Cells were treated with 100 nmol/L MLN4924, 100 nmol/L ara-C, or both drugs for 16 hours. The DNA tail moment for each experimental condition was quantified by alkaline comet assay. Representative images are shown. $n = 3 \pm$ SD. *, $P < 0.05$ indicates a significant difference from either single-agent treatment.
Moreover, primary cells from chemo-naïve newly diagnosed (n = 4) and previously treated patients (n = 6) with AML did not differ in their sensitivity to the MLN4924/ara-c combination (Fig. 1B). Patient characteristics are detailed in Supplementary Table S1. Consistent with the results of our cell viability analyses, cotreatment with MLN4924 and ara-C resulted in significantly greater diminished clonogenic survival (Fig. 1C) and levels of drug-induced apoptosis (Fig. 1D) than exposure to either drug alone.

The combination of MLN4924 and ara-C promotes increased levels of DNA damage

The induction of DNA damage is one of the hallmark features of the anticancer mechanism of action of ara-C and other nucleoside analogs. We and others have also demonstrated that MLN4924 triggers DNA damage by promoting CDT-1–dependent DNA re-replication (15, 17, 26). We hypothesized that cotreatment with MLN4924 and ara-C would yield significantly greater levels of DNA damage. Accordingly, MLN924 and ara-C cooperated to stimulate the increased levels of the phosphorylated (active) form of the DNA damage sensor CHK1 (Ser317), and the DNA damage marker γH2AX (Fig. 2A). These effects coincided with an elevation in the expression of the cyclin-dependent kinase inhibitor p27 and the active form of caspase-3, which would be expected based upon the combined effects of these agents on cell viability and apoptosis shown in Fig. 1. We next conducted alkaline comet assays to generate another readout of drug-induced DNA damage. These experiments demonstrated that the MLN4924/ara-C combination significantly increased the DNA tail moment, indicating heightened levels of DNA damage (Fig. 2B and C).

CDT1 stabilization is not essential for the proapoptotic effects of the MLN4924/ara-C combination

As mentioned earlier, CDT1 stabilization has been previously suggested to be an important pharmacodynamic effect that facilitates DNA damage and contributes to the anticancer activity of MLN4924. To investigate whether this specific effect may be responsible, at least in part, for the benefit we observed with the MLN4924/ara-C combination, we utilized shRNA to target its expression in MOLM-13 cells. Knockdown efficiency was assessed by immunoblotting (Fig. 3A). A comparison of the proapoptotic effects of the MLN4924/ara-C combination in the presence and absence of CDT1 shRNA showed that CDT1 expression levels had a modest impact on single-agent MLN4924 treatment, but had a negligible effect on the combination of both drugs (Fig. 3B). These results suggest that other aspects of the mechanism of action of MLN4924 may be mediating its ability to augment ara-C activity.

MLN4924 disrupts nucleotide metabolism and diminishes endogenous nucleotide pools

We next conducted global metabolic profiling to obtain a more comprehensive assessment of the pharmacodynamic effects of MLN4924. MV4-11 cells were treated with 100 nmol/L MLN4924 for 12 and 24 hours. A total of 268 distinct biochemicals were specifically identified and quantified in experimental samples. Heatmap analysis revealed that exposure to MLN4924 caused time-dependent alterations in multiple metabolic superpathways (Fig. 4A). Quantification of individual biochemicals revealed that the levels of 112 bio-

chemicals (19 increased and 93 decreased) were significantly altered (P < 0.05) following 12-hour treatment with MLN4924 compared with controls. Additional exposure to MLN4924 (24 hours) resulted in 199 significant alterations (53 increased and 146 decreased, P < 0.05). The overall trend at both time-points indicated impairment rather than activation of the majority of the affected superpathways.

Figure 3. CDT1 stabilization is not required for MLN4924 to augment ara-C activity. A, knockdown of CDT1. Lentiviral shRNA was utilized to knock down CDT1 expression. MOLM-13 cells infected with CDT1-directed or nontargeted control shRNA were treated with 100 nmol/L MLN4924, 100 nmol/L ara-C, or both drugs for 24 hours. Knockdown efficiency was evaluated by immunoblotting. Tubulin documented equal protein loading. B, CDT1 impairment does not significantly impact the proapoptotic effects of the MLN4924/ara-C combination. Cells infected with nontargeted control or CDT1-directed shRNA were treated with 100 nmol/L MLN4924, 100 nmol/L ara-C, or both drugs for 48 hours. Drug-induced apoptosis was quantified by PI/FACS analysis. n = 3 ± SD.
Figure 4. MLN4924 disrupts nucleotide metabolism in AML cells. A, cells were treated with 100 nmol/L MLN4924 for 12 and 24 hours. Cells were processed for global metabolic analyses as described in the Materials and Methods. Heatmap depicts superpathway analysis for both timepoints. Changes for each timepoint are quantified relative to control; $n = 4$ for each experimental condition. B, cells were treated with 100 nmol/L MLN4924 for 12 and 24 hours. Cells were processed for global metabolic analyses as described in the Materials and Methods. Heatmap specifically depicts nucleotide metabolism pathway analysis for both timepoints. Changes for each timepoint are quantified relative to control; $n = 4$ for each experimental condition.
MLN4924 facilitates increased incorporation of ara-C into the DNA of AML cells.

We hypothesized that the therapeutic benefit derived from combining MLN4924 with ara-C could be, in part, due to increased DNA incorporation of ara-C facilitated by reduced competition from endogenous nucleotides/nucleosides. To test this possibility, we quantified the inclusion of radiolabeled [3H]ara-C into the DNA of established and primary AML cells in the presence and absence of MLN4924. Notably, the quantity of [3H]ara-C was significantly higher in cells cotreated with MLN4924 in both established and primary AML cells (Fig. 5A).

We next sought to determine whether this effect could be overcome by exogenous supplementation with the nucleotide building block ribose to antagonize the nucleotide depletion caused by MLN4924 treatment. As shown in Fig. 5A, the addition of ribose significantly blunted the enhancement of [3H]ara-C incorporation that we observed in the presence of MLN4924. Accordingly, quantification of drug-induced apoptosis triggered by the MLN4924/ara-C combination in the presence and absence of ribose supplementation showed that in addition to diminishing the integration of [3H]ara-C into DNA, exogenous ribose also tempered MLN4924/ara-C–induced cell death (Fig. 5B). Our collective results demonstrate that the combination benefit of MLN4924 and ara-C is at least partially due to elevated incorporation of ara-C into the DNA of AML cells.

The combination of MLN4924 and ara-C effectively inhibits the progression of FLT3-ITD+ AML xenografts in vivo.

The in vivo anticancer activity of the MLN4924/ara-C combination was evaluated by administering vehicle control, MLN4924 (60 mg/kg BID), ara-C (50 mg/kg QD), or both drugs to mice implanted with MOLM-13 FLT3-ITD+ xenografts. Both MLN4924 and ara-C monotherapies significantly inhibited disease progression (Fig. 6A). Coadministration of MLN4924 and ara-C provided a significantly greater therapeutic benefit than either drug alone and resulted in stable inhibition of disease progression throughout our study. The combination was well tolerated and no notable toxicities were observed other than a very modest reduction in mean body weight. IHC analysis of specimens collected from animals in all experimental groups demonstrated superior in vivo...
growth inhibition (elevated p27 and reduced PCNA levels), augmented DNA damage (γH2AX), and increased apoptosis (cleaved caspase-3) following treatment with the MLN4924/ara-C combination compared with either single agent (Fig. 6B and Supplementary Fig. S4).

**Discussion**

Cytotoxic-based therapy remains the standard for the treatment of AML, and has changed little in the past four decades. New agents/strategies for AML therapy are clearly needed in general, but are urgently needed for patients that have unfavorable cytogenetics and/or are older and unfit for cytotoxic induction chemotherapy as they have the lowest probability of achieving long-term survival (<20%) with existing therapies (4, 27, 28). Inhibition of the NEDDylation pathway with the investigational drug MLN4924 is a novel therapeutic approach that has demonstrated encouraging anti-AML activity in the preclinical and clinical setting (15, 16).

However, our understanding of the pharmacodynamic effects of MLN4924 that are responsible for its therapeutic activity in AML remains incomplete. We hypothesized that MLN4924 may augment the efficacy of ara-C based on its DNA-damaging properties that we and others have reported. Our initial data supported this hypothesis. Yet, targeted knockdown of CDT1, a chromatin licensing factor and NEDD8 substrate that has been suggested to be a key mediator of MLN4924’s DNA-damaging properties and overall anticancer activity, did not indicate that it was an important regulator of sensitivity to the MLN4924/ara-C combination. We subsequently conducted global metabolic profiling of AML cells treated with MLN4924 to identify additional pharmacodynamic effects that may promote sensitization to ara-C. Our results showed that inhibition of NEDD8-mediated protein turnover has effects on multiple metabolic superpathways, but was particularly effective at antagonizing both purine and pyrimidine nucleotide metabolism. Although several preclinical studies have reported on the pharmacodynamic characteristics of MLN4924 (29), our investigation is the first to report the specific drug-related effects on nucleotide metabolism. In addition to establishing a new link between NEDD8-mediated protein turnover and nucleotide homeostasis, our findings demonstrate the value of global metabolic profiling in the pharmacodynamic analysis of investigational anticancer agents.

The MLN4924-induced disruption of nucleotide homeostasis that we observed provided a potential mechanistic explanation underlying its ability to improve the activity of the nucleoside analog ara-C. We hypothesized that the depletion of endogenous nucleotide pools by MLN4924 would yield more efficient incorporation of ara-C into the DNA of AML cells. A series of experiments demonstrated the benefit of the MLN4924/ara-C combination, which was due, at least in part, to MLN4924-mediated heightened incorporation of ara-C into DNA. This newly discovered DNA-related pharmacodynamic effect of MLN4924 builds upon several earlier investigations, which reported that the DNA-damaging properties of MLN4924 are linked to the stabilization of the chromatin licensing factor CDT1 and subsequent DNA replication stress (14, 26, 30–32).

Another interesting aspect of our study is related to the similar sensitivity of the primary AML cells from both newly diagnosed and previously treated patients with AML to the MLN4924/ara-C combination. Although the number of specimens we analyzed is relatively small (n = 4 newly diagnosed, n = 6 previously treated), the benefit we observed in cells that were clinically refractory to the ara-C based “7+3” regimen could have important translational implications. It is possible that NEDDylation may play a previously unstudied role in ara-C resistance and that inhibiting the pathway with MLN4924 may be sufficient to counter resistance to ara-C and other anticancer agents. Further investigation is required to fully evaluate this possibility, but the complete responses of refractory AML patients that were observed in the phase I clinical trial of MLN4924 are encouraging (16). Moreover, the ability of MLN4924 to antagonize drug resistance does not appear to be restricted to AML and/or the conventional agents that are used to treat this disease. We recently showed that MLN4924 resensitizes cisplatin-resistant ovarian cancer cells to platinum chemotherapy (17). Our findings about the ability of MLN4924 to overcome platinum resistance were confirmed shortly after our initial report by an independent research team (33). These observations suggest that the mechanisms of resistance to MLN4924 do not directly overlap with those of cytotoxic chemotherapeutic agents and that NEDD8-mediated protein turnover may play a more significant role in controlling chemosensitivity than previously known.

At a minimum, these observations provide rationales to further explore potential applications for MLN4924 in the treatment of malignancies that are resistant to cytotoxic chemotherapy and to more rigorously study the mechanisms by which aberrant NEDDylation promotes malignant progression and drug resistance. The identification of a predictive biomarker of sensitivity to MLN4924 would also be a significant catalyst to its successful clinical development. Despite extensive ongoing preclinical and clinical research efforts with MLN4924, no specific predictive biomarker has been identified to date. The increasingly more powerful dataset that is developing as additional patients are treated with MLN4924 on clinical studies may help to address this issue.

In conclusion, our data establish that inhibition of NAE with MLN4924 is a novel strategy to augment the efficacy of ara-C. A clinical trial further investigating the safety and efficacy of MLN4924 in combination with ara-C therapy is warranted with ultimate comparison to LDAC monotherapy in older adults with AML. Considering the dramatic MLN4924-induced disruption of both purine and pyrimidine nucleotide metabolism we observed in this study, this approach may also have potential applications for other malignancies that use nucleoside analog-based therapy.

**Disclosure of Potential Conflicts of Interest**

M. Keaton is an employee of Metabolon. No potential conflicts of interest were disclosed by the other authors.

**Authors’ Contributions**

Grant Support
This work was supported by a grant from the National Cancer Institute (R01CA172443) to J. Carew.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received August 5, 2014; revised October 21, 2014; accepted October 27, 2014; published OnlineFirst November 11, 2014.

References
24. Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, Pesenti E, et al. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resis-
tant BCR-ABL mutations including T315I. Blood 2008;111:4155–64.
26. Milhollen MA, Narayanani U, Soucy TA, Veiby PO, Smith PG, Amidon B. Inhibition of NEDD8-activating enzyme induces reperfusion and apo-
30. Wei D, Li H, Yu J, Sebolt JT, Zhao L, Lawrence TS, et al. Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-
32. Wei D, Li H, Yu J, Sebolt JT, Zhao L, Lawrence TS, et al. Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-

www.aacrjournals.org
Cancer Clin Res; 2(2) January 15, 2015 447
The NEDD8-Activating Enzyme Inhibitor MLN4924 Disrupts Nucleotide Metabolism and Augments the Efficacy of Cytarabine

Steffan T. Nawrocki, Kevin R. Kelly, Peter G. Smith, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-14-1960

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2014/11/12/1078-0432.CCR-14-1960.DC1

Cited articles
This article cites 33 articles, 21 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/21/2/439.full.html#ref-list-1

Citing articles
This article has been cited by 6 HighWire-hosted articles. Access the articles at:
/content/21/2/439.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.